Y-Intercept (HK)’s Encompass Health EHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$903K Sell
7,431
-41,060
-85% -$4.84M 0.02% 1060
2026
Q2
$4.9M Sell
48,491
-17,724
-27% -$1.84M 0.1% 281
2026
Q1
$6.4M Sell
66,215
-28,247
-30% -$2.9M 0.12% 238
2025
Q4
$10M Buy
94,462
+87,460
+1,249% +$10.1M 0.22% 69
2025
Q3
$889K Sell
7,002
-14,889
-68% -$1.77M 0.02% 1030
2025
Q2
$2.68M Buy
21,891
+16,908
+339% +$1.93M 0.07% 470
2025
Q1
$505K Buy
+4,983
New +$487K 0.03% 695
2024
Q4
– Sell
-9,720
Closed -$939K – 1298
2024
Q3
$939K Buy
+9,720
New +$873K 0.06% 472
2024
Q1
– Sell
-7,308
Closed -$488K – 1465
2023
Q4
$488K Buy
+7,308
New +$473K 0.05% 611
2022
Q3
– Sell
-9,664
Closed -$431K – 1052
2022
Q2
$431K Buy
9,664
+5,507
+132% +$283K 0.06% 472
2022
Q1
$235K Buy
+4,157
New +$217K 0.05% 554
2021
Q1
– Sell
-3,591
Closed -$235K – 663
2020
Q4
$235K Buy
+3,591
New +$211K 0.1% 402

Other funds holding EHC

Y-Intercept (HK)'s EHC Position: Q3 2026 in Review

Y-Intercept (HK) reduced its Encompass Health (EHC) stake by 85% in Q3 2026, selling an estimated $4.84M and leaving 7,431 shares worth $903K. The position accounts for 0.02% of the portfolio, ranked #1060.

Y-Intercept (HK) first reported a position in EHC in Q4 2020 and has held it in 12 quarters since. The position peaked at $10M in Q4 2025. 371 funds tracked by Wall St. Rank hold EHC as of Q3 2026.

  • Y-Intercept (HK) held 7,431 shares of Encompass Health worth $903K as of Q3 2026.
  • Y-Intercept (HK) sold 41,060 Encompass Health shares in Q3 2026, an estimated $4.84M.
  • Encompass Health made up 0.02% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1060 holding.
  • Y-Intercept (HK) first reported a position in Encompass Health in Q4 2020 and has held it in 12 quarters since.
  • Y-Intercept (HK)'s Encompass Health position peaked at $10M in Q4 2025.
  • 371 funds tracked by Wall St. Rank held Encompass Health as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.